Evexia Lifecare

Why is Evexia Lifecare Ltd falling/rising?

As of 10-Aug, Evexia Lifecare Ltd's stock price is rising to 1.53, driven by a 2.68% increase, strong investor interest, and outperformance against its sector. The stock has shown a positive trend with consecutive gains and is currently above several moving averages, indicating bullish momentum.

As of 10-Aug, Evexia Lifecare Ltd's stock price is rising, currently at 1.53, with a change of 0.04 or 2.68%. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 3.22% today and has been on a consecutive gain streak for the last three days, accumulating a total return of 7.75% during this period. Additionally, there has been a notable rise in investor participation, with delivery volume increasing by 98.11% against the five-day average, indicating heightened interest and activity in the stock. <BR><BR>Moreover, the current price is higher than the 5-day, 100-day, and 200-day moving averages, suggesting a positive short-term trend, although it remains lower than the 20-day and 50-day moving averages. Overall, these factors contribute to the upward movement of Evexia Lifecare Ltd's stock price.

Which are the latest news on Evexia Lifecare?

Should I buy, sell or hold Evexia Lifecare Ltd?

Are Evexia Lifecare Ltd latest results good or bad?

Evexia Lifecare Ltd's latest Q4 FY26 results show significant improvements, with a net profit increase of 168.97% quarter-on-quarter and net sales up 45.76%. However, the company's long-term performance has been concerning, with declining sales and profits over the past five years, suggesting caution for investors.

Evexia Lifecare Ltd's latest results for Q4 FY26 show a significant improvement compared to previous quarters, indicating a positive trend. The company reported a net profit of ₹0.78 crores, which represents a remarkable increase of 168.97% quarter-on-quarter and 151.61% year-on-year. Additionally, net sales reached ₹36.79 crores, marking a 45.76% increase from the previous quarter and a 55.82% increase year-on-year.<BR><BR>The operating margin also improved to 3.02% from 0.99% in the previous quarter, and the PAT margin rose to 2.12% from 1.15%. These figures suggest that the company is making strides in enhancing its profitability and operational efficiency.<BR><BR>However, it's important to consider the broader context. Despite this positive quarterly performance, Evexia Lifecare has faced significant challenges over the past five years, including a decline in sales and operating profits. The company's long-term track record shows a compound annual growth rate (CAGR) of negative 7.97% in sales and negative 23.63% in EBIT, which raises concerns about its sustainability.<BR><BR>Additionally, the stock remains under pressure, trading at a steep discount from its 52-week high, and the overall market sentiment appears cautious due to the company's historical volatility and operational inefficiencies.<BR><BR>In summary, while the latest quarterly results are strong and indicate a positive turnaround, the company's long-term performance and financial health remain areas of concern. Investors should weigh these factors carefully when considering their positions in Evexia Lifecare.

When is the next results date for Evexia Lifecare Ltd?

The next results date for Evexia Lifecare Ltd is 07 August 2026.

The next results date for Evexia Lifecare Ltd is scheduled for 07 August 2026.

How big is Evexia Lifecare?

As of 10th June, Evexia Lifecare Ltd has a market capitalization of 312.00 Cr, with recent net sales of 109.85 Cr and a net profit of 2.07 Cr over the last four quarters. Shareholder's funds are valued at 129.40 Cr, and total assets amount to 883.00 Cr.

As of 10th June, <BR><BR>Market Cap: Evexia Lifecare Ltd has a market capitalization of 312.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 109.85 Cr, while the sum of Net Profit for the same period is 2.07 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds are valued at 129.40 Cr, and Total Assets amount to 883.00 Cr.

Who are in the management team of Evexia Lifecare?

The management team of Evexia Lifecare includes Jayesh R Thakkar (Chairman & Managing Director), Kartik Mistry, Chandresh Kumar Vishnubhai Kahar, Hasmukhbhai Thakkar, Naresh Arvindbhai Patel, Payal Gajjar (all Independent Directors), Parul Samalia (Company Secretary & Compliance Officer), and Parth Patel (Additional Director). They oversee the company's strategic direction and regulatory compliance.

The management team of Evexia Lifecare includes the following individuals:<BR><BR>1. **Jayesh R Thakkar** - Chairman & Managing Director<BR>2. **Kartik Mistry** - Independent Director<BR>3. **Chandresh Kumar Vishnubhai Kahar** - Independent Director<BR>4. **Hasmukhbhai Thakkar** - Independent Director<BR>5. **Naresh Arvindbhai Patel** - Independent Director<BR>6. **Payal Gajjar** - Independent Director<BR>7. **Parul Samalia** - Company Secretary & Compliance Officer<BR>8. **Parth Patel** - Additional Director<BR><BR>This team is responsible for guiding the company's strategic direction and ensuring compliance with regulatory standards.

Who are the peers of the Evexia Lifecare?

Evexia Lifecare's peers include CIAN Agro, Sundrop Brands, Shri Venkatesh, Kriti Nutrients, Gokul Refoils, Integ. Proteins, Vijay Solvex, Ajanta Soya, and M K Proteins. CIAN Agro leads in management quality and growth, while Evexia Lifecare has average management risk and a 1-year return of -32.40%.

Peers: The peers of Evexia Lifecare are CIAN Agro, Sundrop Brands, Shri Venkatesh, Kriti Nutrients, Gokul Refoils, Integ. Proteins, Vijay Solvex, Ajanta Soya, and M K Proteins.<BR><BR>Quality Snapshot: Excellent management risk is observed at CIAN Agro, while Good management risk is found at Kriti Nutrients. Average management risk is present at Sundrop Brands, Shri Venkatesh, Gokul Refoils, Evexia Lifecare, Ajanta Soya, and M K Proteins, and the rest. Below Average management risk is noted at Integ. Proteins, Vijay Solvex, and Ramdevbaba Sol. Growth is excellent at CIAN Agro, while Average growth is seen at Integ. Proteins, and the rest have Below Average growth. Capital Structure is excellent at Sundrop Brands, Kriti Nutrients, Ajanta Soya, and M K Proteins, while Below Average capital structure is noted at CIAN Agro, Shri Venkatesh, Gokul Refoils, Evexia Lifecare, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is CIAN Agro at 208.44%, while the lowest is Ajanta Soya at -47.07%. Evexia Lifecare's 1-year return is -32.40%, which is higher than Ajanta Soya's but lower than CIAN Agro's. Additionally, Gokul Refoils, Vijay Solvex, M K Proteins, and Ramdevbaba Sol. have negative six-month returns.

What does Evexia Lifecare do?

Evexia Lifecare Ltd operates in the Edible Oil industry as a Micro Cap company, reporting net sales of 37 Cr and a net profit of 1 Cr for March 2026. The company, formerly known as Jal Hi Power Petrochem Limited, was renamed on December 1, 2020.

Overview:<BR>Evexia Lifecare Ltd operates in the Edible Oil industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as Jal Hi Power Petrochem Limited in 1990, underwent several name changes, and was last renamed Evexia Lifecare Limited on December 01, 2020. The most recent quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 37 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 312 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 148.00<BR>- Industry P/E: 14<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 2.24<BR>- Return on Equity: 0.26%<BR>- Price to Book: 0.59<BR><BR>Contact Details:<BR>Address: Village - Tundao, Tal Savli Vadodara Gujarat : 391775<BR>Tel: 91-265-2362200/2361100<BR>Email: kavitindustrieslimited@gmail.com<BR>Website: http://www.evexialifecare.com

How has been the historical performance of Evexia Lifecare?

Evexia Lifecare's historical performance shows significant sales growth from 56.29 Cr in Mar'24 to 110.48 Cr in Mar'25, despite previous declines. While operating profit improved, profitability metrics decreased, and total liabilities rose, indicating a mixed financial outlook.

Answer:<BR>The historical performance of Evexia Lifecare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Evexia Lifecare's net sales increased from 56.29 Cr in Mar'24 to 110.48 Cr in Mar'25, marking a substantial growth. However, net sales had previously declined from 69.55 Cr in Mar'23 to 56.29 Cr in Mar'24. The total operating income followed a similar trend, rising to 110.48 Cr in Mar'25 from 56.29 Cr in Mar'24, after a dip in the preceding years. The total expenditure, excluding depreciation, also increased to 106.40 Cr in Mar'25 from 54.31 Cr in Mar'24, reflecting higher costs associated with the increased sales. Operating profit (PBDIT) improved to 4.22 Cr in Mar'25 from 2.85 Cr in Mar'24, indicating better operational efficiency. Profit before tax showed a slight decrease to 1.44 Cr in Mar'25 from 1.93 Cr in Mar'24, while profit after tax also declined to 0.93 Cr in Mar'25 from 1.38 Cr in Mar'24. The company's total liabilities rose to 883.00 Cr in Mar'24 from 847.50 Cr in Mar'23, with long-term borrowings remaining significant at 676.64 Cr in Mar'24. Cash flow from operating activities improved to 17.00 Cr in Mar'24, contrasting with a negative cash flow in the previous year, while cash flow from investing activities saw a substantial outflow of -17.00 Cr in Mar'24. Overall, Evexia Lifecare's financial performance reflects a recovery in sales and operational profit, despite challenges in profitability and increasing liabilities.

Is Evexia Lifecare overvalued or undervalued?

As of October 23, 2025, Evexia Lifecare is considered overvalued with a high PE ratio of 212.41 and an EV to EBITDA ratio of 206.57, significantly contrasting with its peers, and has underperformed the market with a year-to-date decline of 42.61%.

As of 23 October 2025, Evexia Lifecare's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, based on the current financial metrics, the company remains overvalued. The PE ratio stands at an exceptionally high 212.41, while the EV to EBITDA ratio is also elevated at 206.57, suggesting that the market is pricing in significant growth expectations that may not be justified by the company's performance.<BR><BR>In comparison to its peers, Evexia Lifecare's ratios starkly contrast with those of Gulf Oil Lubricants and Veedol Corporation, which have PE ratios of 16.16 and 16.62, respectively, and EV to EBITDA ratios of 10.99 and 14.69. These peers are classified as very attractive, highlighting the disparity in valuation. Furthermore, Evexia's return metrics are concerning, with a year-to-date decline of 42.61%, significantly underperforming the Sensex's 8.21% gain during the same period. This underperformance reinforces the view that Evexia Lifecare is overvalued in the current market environment.

Who are the top shareholders of the Evexia Lifecare?

The top shareholders of Evexia Lifecare include Aio Growth Capital Fund Spc at 12.17%, Raghuvir International at 1.55%, and individual investors holding 36.68%. There is minimal mutual fund and foreign institutional investor involvement, with no pledged promoter holdings.

The top shareholders of Evexia Lifecare include a mix of individual and institutional investors. The largest public shareholder is Aio Growth Capital Fund Spc, holding 12.17%. Among the promoters, Raghuvir International has the highest holding at 1.55%. Additionally, individual investors collectively hold a significant portion, accounting for 36.68% of the shares. The company also has some mutual fund involvement, with three schemes holding a total of 0.02%, and one foreign institutional investor (FII) holding 0.16%. Notably, there are no pledged promoter holdings.

What is the technical trend for Evexia Lifecare?

As of June 2, 2025, Evexia Lifecare's trend has shifted to bearish with moderate strength, supported by bearish indicators from moving averages and Bollinger Bands, despite mixed signals from the KST and MACD.

As of 2 June 2025, the technical trend for Evexia Lifecare has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating a divergence in momentum. Both the weekly and monthly Bollinger Bands are bearish, reinforcing the negative trend. Daily moving averages are also bearish, suggesting continued downward pressure. The KST shows mixed signals with a mildly bullish weekly reading and a mildly bearish monthly reading. Overall, the lack of clear signals from the RSI and Dow Theory indicates a weak trend, further supporting the bearish outlook.

What is the bonus history of the Evexia Lifecare?

Evexia Lifecare issued a bonus on October 23, 2015, in a 1:3 ratio, granting one additional share for every three shares held, with the record date set for October 26, 2015.

Evexia Lifecare has a bonus history that includes a notable issue on October 23, 2015. The company announced a bonus in a ratio of 1:3, meaning that for every three shares held, shareholders received one additional share. The record date for this bonus was October 26, 2015, which is when the eligibility for receiving the bonus shares was determined. If you have any more questions about Evexia Lifecare or need further details, feel free to ask!

Has Evexia Lifecare declared dividend?

No Dividend History Available